TY - JOUR AU - Li, Li AU - Zhou, Jiawei AU - Wang, Shuai AU - Jiang, Lei AU - Chen, Xiaoyan AU - Zhou, Yangfan AU - Li, Jingke AU - Shi, Jingqi AU - Liu, Pu AU - Shu, Zheyue AU - Gonzalez, Frank J. AU - Liu, Aiming AU - Hu, Hu PY - 2022/06/01 Y2 - 2024/03/29 TI - Critical role of peroxisome proliferator-activated receptor α in promoting platelet hyperreactivity and thrombosis under hyperlipidemia JF - Haematologica JA - haematol VL - 107 IS - 6 SE - Articles DO - 10.3324/haematol.2021.279770 UR - https://haematologica.org/article/view/haematol.2021.279770 SP - 1358-1373 AB - Platelet hyperreactivity and increased atherothrombotic risk are specifically associated with dyslipidemia. Peroxisome proliferator-activated receptor alpha (PPARα) is an important regulator of lipid metabolism. It has been suggested to affect both thrombosis and hemostasis, yet the underlying mechanisms are not well understood. In this study, the role and mechanism of PPARα in platelet activation and thrombosis related to dyslipidemia were examined. Employing mice with deletion of PPARα (Pparα-/-), we demonstrated that PPARa is required for platelet activation and thrombus formation. The effect of PPARα is critically dependent on platelet dense granule secretion, and is contributed by p38MAPK/Akt, fatty acid b-oxidation, and NAD(P)H oxidase pathways. Importantly, PPARα and the associated pathways mediated a prothrombotic state induced by a high-fat diet and platelet hyperactivity provoked by oxidized low density lipoproteins. Platelet reactivity was positively correlated with the levels of expression of PPARα, as revealed by data from wild-type, chimeric (Pparα+/-), and Pparα-/- mice. This positive correlation was recapitulated in platelets from hyperlipidemic patients. In a lipid-treated megakaryocytic cell line, the lipid-induced reactive oxygen species-NF-kB pathway was revealed to upregulate platelet PPARα in hyperlipidemia. These data suggest that platelet PPARα critically mediates platelet activation and contributes to the prothrombotic status under hyperlipidemia. ER -